Foghorn Therapeutics Inc. business relationships
Companies named in Foghorn Therapeutics Inc.’s 10-K filed 2026-03-11, and public companies whose annual reports name Foghorn Therapeutics Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 2% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Foghorn Therapeutics Inc.’s annual report 3
“Exclusive Collaboration and License Agreement, by and between Merck Sharp & Dohme Corp. and Foghorn Therapeutics Inc., dated as of July 2, 2020 (Incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 202...” SEC filing
“The Company accounted for the arrangement under ASC 606 as the Company concluded it has a customer relationship with Lilly.” SEC filing
“• Advance our lead precision oncology product candidate, FHD-909, through clinical development in patients with NSCLC and with select solid tumors with partner Lilly.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.